Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer

Plasma androgen receptor (AR) gain identifies metastatic castration-resistant prostate cancer (mCRPC) patients with worse outcome on abiraterone/enzalutamide, but its relevance in the context of taxane chemotherapy is unknown. We aimed to evaluate whether docetaxel is active regardless of plasma AR...

Descripción completa

Detalles Bibliográficos
Autores principales: Conteduca, Vincenza, Jayaram, Anuradha, Romero-Laorden, Nuria, Wetterskog, Daniel, Salvi, Samanta, Gurioli, Giorgia, Scarpi, Emanuela, Castro, Elena, Marin-Aguilera, Mercedes, Lolli, Cristian, Schepisi, Giuseppe, Maugeri, Antonio, Wingate, Anna, Farolfi, Alberto, Casadio, Valentina, Medina, Ana, Puente, Javier, Vidal, Mª José Méndez, Morales-Barrera, Rafael, Villa-Guzmán, Jose C., Hernando, Susana, Rodriguez-Vida, Alejo, González-del-Alba, Aránzazu, Mellado, Begoña, Gonzalez-Billalabeitia, Enrique, Olmos, David, Attard, Gerhardt, De Giorgi, Ugo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377278/
https://www.ncbi.nlm.nih.gov/pubmed/30773204
http://dx.doi.org/10.1016/j.eururo.2018.09.049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377278/
https://www.ncbi.nlm.nih.gov/pubmed/30773204
http://dx.doi.org/10.1016/j.eururo.2018.09.049

Ejemplares similares